Shenbin Liu1,2, Jing Feng1, Jialie Luo1, Pu Yang1, Thomas J Brett3, Hongzhen Hu1. 1. Department of Anesthesiology, The Center for the Study of Itch, Washington University School of Medicine, St. Louis, MO, 63110, USA. 2. Department of Integrative Medicine and Neurobiology, State Key Laboratory of Medical Neurobiology, Shanghai Medical College, Fudan University, Shanghai, 200032, China. 3. Department of Internal Medicine, Washington University School of Medicine, St. Louis, MO, 63110, USA.
Abstract
BACKGROUND AND PURPOSE: TMEM16A, also known as anoctamin 1 channel, is a member of the Ca(2+)-activated chloride channels family and serves as a heat sensor in the primary nociceptors. Eact is a recently discovered small molecule activator of the TMEM16A channel. Here, we asked if Eact produces pain- and itch-related responses in vivo and investigated the cellular and molecular basis of Eact-elicited responses in dorsal root ganglia (DRG) neurons. EXPERIMENTAL APPROACH: We employed behavioural testing combined with pharmacological inhibition and genetic ablation approaches to identify transient receptor potential vanilloid 1 (TRPV1) as the prominent mediator for Eact-evoked itch- or pain-related responses. We investigated the effects of Eact on TRPV1 and TMEM16A channels expressed in HEK293T cells and in DRG neurons isolated from wild type and Trpv1(-/-) mice using Ca(2+) imaging and patch-clamp recordings. We also used site-directed mutagenesis to determine the molecular basis of Eact activation of TRPV1. KEY RESULTS: Administration of Eact elicited both itch- and pain-related behaviours. Unexpectedly, the Eact-elicited behavioural responses were dependent on the function of TRPV1, as shown by pharmacological inhibition and genetic ablation studies. Eact activated membrane currents and increased intracellular free Ca(2+) in both TRPV1-expressing HEK293T cells and isolated DRG neurons in a TRPV1-dependent manner. Eact activation of the TRPV1 channel was severely attenuated by mutations disrupting the capsaicin-binding sites. CONCLUSIONS AND IMPLICATIONS: Our results suggest that Eact activates primary sensory nociceptors and produces both pain and itch responses mainly through direct activation of TRPV1 channels.
BACKGROUND AND PURPOSE:TMEM16A, also known as anoctamin 1 channel, is a member of the Ca(2+)-activated chloride channels family and serves as a heat sensor in the primary nociceptors. Eact is a recently discovered small molecule activator of the TMEM16A channel. Here, we asked if Eact produces pain- and itch-related responses in vivo and investigated the cellular and molecular basis of Eact-elicited responses in dorsal root ganglia (DRG) neurons. EXPERIMENTAL APPROACH: We employed behavioural testing combined with pharmacological inhibition and genetic ablation approaches to identify transient receptor potential vanilloid 1 (TRPV1) as the prominent mediator for Eact-evoked itch- or pain-related responses. We investigated the effects of Eact on TRPV1 and TMEM16A channels expressed in HEK293T cells and in DRG neurons isolated from wild type and Trpv1(-/-) mice using Ca(2+) imaging and patch-clamp recordings. We also used site-directed mutagenesis to determine the molecular basis of Eact activation of TRPV1. KEY RESULTS: Administration of Eact elicited both itch- and pain-related behaviours. Unexpectedly, the Eact-elicited behavioural responses were dependent on the function of TRPV1, as shown by pharmacological inhibition and genetic ablation studies. Eact activated membrane currents and increased intracellular free Ca(2+) in both TRPV1-expressing HEK293T cells and isolated DRG neurons in a TRPV1-dependent manner. Eact activation of the TRPV1 channel was severely attenuated by mutations disrupting the capsaicin-binding sites. CONCLUSIONS AND IMPLICATIONS: Our results suggest that Eact activates primary sensory nociceptors and produces both pain and itch responses mainly through direct activation of TRPV1 channels.
Authors: Stephen Ph Alexander; William A Catterall; Eamonn Kelly; Neil Marrion; John A Peters; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Christopher Southan; Jamie A Davies Journal: Br J Pharmacol Date: 2015-12 Impact factor: 8.739
Authors: Kent Miner; Katja Labitzke; Benxian Liu; Paul Wang; Kathryn Henckels; Kevin Gaida; Robin Elliott; Jian Jeffrey Chen; Longbin Liu; Anh Leith; Esther Trueblood; Kelly Hensley; Xing-Zhong Xia; Oliver Homann; Brian Bennett; Mike Fiorino; John Whoriskey; Gang Yu; Sabine Escobar; Min Wong; Teresa L Born; Alison Budelsky; Mike Comeau; Dirk Smith; Jonathan Phillips; James A Johnston; Joseph G McGivern; Kerstin Weikl; David Powers; Karl Kunzelmann; Deanna Mohn; Andreas Hochheimer; John K Sullivan Journal: Front Pharmacol Date: 2019-02-14 Impact factor: 5.810
Authors: Jennifer Danielsson; Aisha S Kuforiji; Gene T Yocum; Yi Zhang; Dingbang Xu; George Gallos; Charles W Emala Journal: Am J Physiol Lung Cell Mol Physiol Date: 2019-11-20 Impact factor: 5.464
Authors: Jing Feng; Pu Yang; Madison R Mack; Dariia Dryn; Jialie Luo; Xuan Gong; Shenbin Liu; Landon K Oetjen; Alexander V Zholos; Zhinan Mei; Shijin Yin; Brian S Kim; Hongzhen Hu Journal: Nat Commun Date: 2017-10-30 Impact factor: 14.919